--- title: "Sana Biotechnology | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285989830.md" datetime: "2026-05-11T20:15:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285989830.md) - [en](https://longbridge.com/en/news/285989830.md) - [zh-HK](https://longbridge.com/zh-HK/news/285989830.md) --- # Sana Biotechnology | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.17, beating the estimate of USD -0.1725. EBIT: As of FY2026 Q1, the actual value is USD -48.61 M. ### Financial Overview #### Cash Position As of March 31, 2026, Sana Biotechnology, Inc.’s cash, cash equivalents, and marketable securities totaled $101.1 million, a decrease from $138.4 million as of December 31, 2025 . This $37.3 million decrease was primarily driven by $37.4 million in cash used in operations . The pro forma cash position was $128.9 million, which includes an approximately $25.0 million equity investment from the Mayo Clinic collaboration and recent at-the-market offering facility (ATM) activity . #### Operating Expenses - **Research and Development Expenses**: For the three months ended March 31, 2026, research and development expenses were $28.7 million, an $8.5 million decrease compared to $37.2 million for the same period in 2025 . This decrease was mainly due to lower personnel-related expenses, including non-cash stock-based compensation ($3.1 million in Q1 2026 vs. $4.6 million in Q1 2025), reduced third-party manufacturing costs, and lower facility and other allocated costs . - **Research and Development Related Success Payments and Contingent Consideration**: Non-cash expenses recognized were $8.4 million for the three months ended March 31, 2026, an increase from $2.0 million for the same period in 2025, reflecting fluctuations in the estimated fair value of liabilities . - **General and Administrative Expenses**: These expenses remained unchanged at $11.5 million for the three months ended March 31, 2026, compared to the same period in 2025, including non-cash stock-based compensation of $2.6 million in Q1 2026 and $2.4 million in Q1 2025 . #### Net Loss - **GAAP Net Loss**: Sana Biotechnology, Inc. reported a net loss of -$47.2 million, or -$0.17 per share, for the three months ended March 31, 2026, an improvement from a net loss of -$49.4 million, or -$0.21 per share, for the same period in 2025 . - **Non-GAAP Net Loss**: The non-GAAP net loss for the three months ended March 31, 2026, was -$38.8 million, or -$0.14 per share, compared to -$47.4 million, or -$0.20 per share, for the same period in 2025 . #### Cash Flow - **Non-GAAP Operating Cash Burn**: Non-GAAP operating cash burn for the three months ended March 31, 2026, was -$37.0 million, an improvement from -$46.6 million for the same period in 2025 . #### Balance Sheet Data (as of March 31, 2026) - **Total Assets**: $373,593 thousand, a decrease from $416,890 thousand as of December 31, 2025 . - **Total Liabilities**: $254,353 thousand, a decrease from $256,006 thousand as of December 31, 2025 . - **Total Stockholders’ Equity**: $119,240 thousand, a decrease from $160,884 thousand as of December 31, 2025 . ### Operational Metrics Sana Biotechnology, Inc. announced a strategic collaboration with Mayo Clinic, including an approximately $25.0 million equity investment, focused on improving care in type 1 diabetes and accelerating the development of SC451 . The company reported positive clinical results at 14 months from an ongoing trial transplanting UP421 without immunosuppression into a patient with type 1 diabetes, demonstrating ongoing survival and function of pancreatic beta cells . Progress continues towards starting Phase 1 trials for SC451 and SG293 in non-Hodgkin lymphoma later this year, with manufacturing readiness and preclinical data preparations underway . Brian Piper was appointed as Executive Vice President, Chief Financial Officer . ### Outlook / Guidance Sana Biotechnology, Inc. expects its cash runway to extend into 2027 . The company anticipates filing an IND and beginning a Phase 1 clinical trial for SC451 as early as this year, and aims to generate first-in-human data for SG293 in non-Hodgkin lymphoma also as early as this year . Furthermore, Sana Biotechnology, Inc. is preparing to begin a clinical trial for SG227 as early as mid-2027, assuming positive early safety and efficacy data for SG293 . ### Related Stocks - [SANA.US](https://longbridge.com/en/quote/SANA.US.md) ## Related News & Research - [Sana Biotechnology Raises $69 Million Through Equity Offering](https://longbridge.com/en/news/286614446.md) - [HC Wainwright Issues Positive Estimate for SANA Earnings](https://longbridge.com/en/news/282980953.md) - [XP Inc. Reports First Quarter 2026 Results | XP Stock News](https://longbridge.com/en/news/286814239.md) - [Donaldson Company dividend preview: 30-year growth streak set to continue](https://longbridge.com/en/news/286805354.md) - [See how the global government debt binge is rippling through markets](https://longbridge.com/en/news/286835671.md)